---
layout: default
title: Acarbose
parent: 僅模型預測 (L5)
nav_order: 63
evidence_level: L5
indication_count: 9
---

# Acarbose
{: .fs-9 }

證據等級: **L5** | 預測適應症: **9** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Acarbose: Evaluation Report — Insufficient Data for Repurposing Assessment

## One-Sentence Summary

Acarbose (DB00284) is a known antidiabetic agent whose original indications are not recorded in this Evidence Pack.
The current TxGNN pipeline returned **no repurposing predictions** for this drug,
and multiple blocking data gaps (MOA, regulatory records, safety data) prevent a complete evaluation at this stage.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in Evidence Pack |
| Predicted New Indication | Not available |
| TxGNN Prediction Score | Not available |
| Evidence Level | L5 — Model prediction not generated; no supporting studies |
| Taiwan Market Status | 未上市 (Not marketed) |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN repurposing prediction is available for Acarbose in this Evidence Pack. As a result, a mechanistic rationale connecting an original indication to a new predicted indication cannot be constructed at this time.

Currently, detailed mechanism of action data is not available in the evidence pack (recorded as a High-severity data gap, DG002). Without MOA information, any mechanistic bridging argument between Acarbose's established therapeutic use and a candidate new indication would be speculative rather than evidence-based.

Additionally, the original indication fields are empty in this Evidence Pack. A complete evaluation requires at minimum: confirmed original indication, TxGNN score and predicted disease target, and MOA data. These prerequisites must be addressed before this section can be meaningfully completed.

---

## Clinical Trial Evidence

Currently no related clinical trials registered (no predicted indication to search against).

---

## Literature Evidence

Currently no related literature available (no predicted indication to search against).

---

## Taiwan Market Information

No regulatory licenses found. Acarbose has **zero recorded authorizations** in the Taiwan FDA database as of the data cutoff (2026-04-19).

---

## Safety Considerations

Please refer to the package insert for safety information.

> All safety fields in this Evidence Pack are recorded as data gaps:
> - Key warnings: not retrieved
> - Contraindications: not retrieved
> - Drug–drug interactions: query returned no results (status: `not_found`)
>
> The TFDA package insert should be consulted directly to obtain warnings and contraindications before any further evaluation step.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack contains no TxGNN repurposing predictions for Acarbose, and two unresolved data gaps (DG001 — Blocking; DG002 — High) prevent entry into even the first stage of safety pre-screening. Proceeding without these inputs would produce an unreliable assessment.

**To proceed, the following is needed:**

- **[DG001 — Blocking]** Retrieve Taiwan FDA package insert (仿單): download PDF from the TFDA website and extract warnings and contraindications to unlock S1 safety pre-screening.
- **[DG002 — High]** Retrieve MOA data from DrugBank API (DB00284) to enable mechanistic relevance analysis.
- **Re-run TxGNN pipeline** to generate predicted indications with scores; the current run returned an empty `predicted_indications` array — verify whether the drug was successfully mapped in the knowledge graph and whether the prediction step executed correctly.
- Once predictions are available, collect clinical trial and literature evidence via ClinicalTrials.gov and PubMed for the top-ranked predicted indication.
- Verify whether Acarbose has any active global approvals (e.g., US FDA, EMA) that were not captured in the Taiwan regulatory query, and cross-check for any relevant real-world indication expansions.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

